ARS Pharma neffy FDA Panel Vote 'Favorable'; Q1 Net Loss $15.0M, Cash $264.5M

ARS Pharmaceuticals, Inc.

2023-Q1 EPS reported -$0.16 revenue$20,000

FDA advisory committee voted 16:6 (adults) and 17:5 (children) that neffy benefit-risk is favorable.
PDUFA target action date anticipated mid-2023; NDA and MAA under review in US and EU.
Cash $264.5M, sufficient for at least three years including planned neffy launch.
Net loss $15.0M for Q1 2023; R&D $6.6M, G&A $12.2M.
Commercial launch prep underway with planned 125-person salesforce.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ARS Pharmaceuticals, Inc. reported the quarter ended March 31, 2023 results: net income $15.0 million.

Period: the quarter ended March 31, 2023
Net income: $15.0 million
Result: reported results

Exact text from the filing

Net loss was $15.0 million for the quarter ended March 31, 2023.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

ARS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-021996

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.